Name for New Modern Analysis with Optical Genome Mapping

• Bionano leaders introduced on the flexibility of optical genome mapping (OGM) to doubtlessly change conventional cytogenetic strategies for structural variant (SV) detection and shared particulars of the corporate’s new product developments

• Bionano and NVIDIA previewed their collaborative improvement, a brand new compute answer for OGM evaluation

• Dr. Alexander Hoischen, Radboud Genomics Know-how Heart, introduced on his expertise utilizing OGM as a alternative for conventional cytogenetic strategies of genome evaluation and shared case research displaying OGM’s potential to determine beforehand undetected SVs related to uncommon illness

• Dr. Adam Smith, College Well being Community, College of Toronto, introduced on his use of VIA™, Bionano’s new software program answer (at the moment in restricted launch), for information filtering and evaluation in hematologic analysis

• Bionano introduced a grant alternative designed to gasoline translational analysis throughout various novel analysis areas utilizing OGM

• On-demand webcasts from the AGBT workshop can be found on the corporate’s web site

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) at the moment introduced particulars of matters lined on the firm’s pre-conference workshop through the Advances in Genome Biology and Know-how (AGBT) 2023 Common Assembly, which passed off February 6-9, 2023 in Hollywood, Florida. Bionano leaders Alka Chaubey, PhD, FACMG, chief medical officer, Alex Hastie, PhD, vp of scientific and scientific affairs, Marc Meyers, head of product administration, and Klint Rose, PhD, fellow, ITP expertise improvement, delivered shows on optical genome mapping (OGM) and its potential to exchange conventional cytogenetic strategies for structural variant (SV) detection, in addition to an outline of the corporate’s new product developments. Damla Senol Cali, PhD, employees software program engineer, {hardware} acceleration at Bionano and George Vacek, PhD, international head of genomics alliances at NVIDIA previewed the businesses’ collaborative improvement, a next-generation compute answer for the evaluation of OGM information from excessive throughput programs . Sheila Purim, PhD, MBA, senior director of phase advertising and marketing, introduced the Bionano Innovator Analysis Grant, which is able to award 5 winners with OGM expertise designed to gasoline analysis in various areas, together with hematologic malignancies, cell remedy, reproductive well being and precision drugs . Adam Smith, PhD, FCCMG, FACMG, erCLG from College Well being Community, College of Toronto, introduced on use of the VIA software program in his scientific analysis, and Alexander Hoischen, PhD, from Radboud Genomics Know-how Heart introduced on use of OGM for SV detection in uncommon diseaseresearch. Bionano and NVIDIA presenters, together with Drs. Smith and Hoischen, additionally participated in reside Q&A periods with the viewers.

Story continues

Bionano and collaborators outlined advances to Bionano’s digital workflow, which may present SV detection related to scientific and translational analysis in areas together with most cancers and genetic illness with better decision and sensitivity than conventional cytogenetic strategies.

• Bionano introduced product developments that may allow larger throughput, enhance information evaluation and reporting, and enhance DNA isolation and extraction: Presenters described upcoming product enhancements, together with the anticipated launches of the Ionic^® system for OGM functions, the excessive throughput Saphyr^® system, the growth of Bionano’s pattern prep menu, and improved evaluation and reporting software program. The presentation from Bionano and NVIDIA launched Bionano’s new compute answer with elevated information processing capabilities, which was co-developed to help larger throughput OGM devices.

• Bionano’s OGM options and VIA software program can supply scientific and translational researchers genome evaluation with excessive decision and sensitivity, a easy workflow, and improved turnaround instances: On the occasion,Dr. Hoischen described how his analysis reveals that OGM can determine extra hidden or missed SVs related to uncommon ailments than conventional strategies. Dr. Smith famous VIA’s potential to offer evaluation and reporting of SVs in a easy report with improved classification and filtering of SVs when in comparison with different reporting software program.

• Bionano launched a grant alternative designed to additional transformational analysis involving SVs utilizing OGM expertise: Dr. Purim shared particulars of Bionano’s new grant program, which is able to award 5 prizes to researchers throughout quite a lot of analysis areas. Grant functions are actually open and can shut in Might 2023.

“Bionano was happy to sponsor the pre-conference workshop at AGBT, the place we shared product improvement plans, information about our strategic collaboration with NVIDIA and an announcement of our Bionano Innovator Analysis Grant. We have been additionally excited to incorporate Drs. Smith and Hoischen in our program, the place they introduced particulars of the modern analysis and information evaluation they’ve carried out using Bionano expertise. AGBT is the place folks come collectively to speak about important advances in genomic expertise, and we have been thrilled to offer convention attendees with an outline of the enhancements we’re making to OGM choices,” commented Erik Holmlin, PhD, president and chief government officer of Bionano Genomics.

A reside webcast of the workshop is accessible right here: https://bionano.com/agbt2023/ Extra particulars concerning the Bionano Innovator Analysis Grant alternative will be discovered right here: www.bionano.com/innovatorgrant

Analysis areas for consideration embrace:

About Bionano Genomics

Bionano Genomics is a supplier of genome evaluation options that may allow researchers and clinicians to disclose solutions to difficult questions in biology and drugs. The Firm’s mission is to rework the way in which the world sees the genome by OGM options, diagnostic companies and software program. The Firm gives OGM options for functions throughout primary, translational and scientific analysis. By means of its Lineagen, Inc. d/b/a Bionano Laboratories enterprise, the Firm additionally gives diagnostic testing for sufferers with scientific shows per autism spectrum dysfunction and different neurodevelopmental disabilities. By means of its BioDiscovery enterprise, the Firm additionally gives an industry-leading, platform-agnostic software program answer, which integrates next-generation sequencing and microarray information designed to offer evaluation, visualization, interpretation and reporting of copy quantity variants, single-nucleotide variants and absence of heterozygosity throughout the genome in a single consolidated view. For extra info, go to www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.

Bionano’s merchandise are for analysis use solely. Not to be used in diagnostic procedures.

Ahead-Wanting Statements of Bionano Genomics

This press launch accommodates forward-looking statements accommodates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995. Phrases similar to “can,” “plan,” “anticipate,” “potential,” and comparable expressions (in addition to different phrases or expressions referencing future occasions, circumstances or circumstances and the negatives thereof) convey uncertainty of future occasions or outcomes and are meant to determine these forward-looking statements. Ahead-looking statements embrace statements relating to our intentions, beliefs, projections, outlook, analyzes or present expectations regarding, amongst different issues: (1) the affect and utility of optical genome mapping (OGM) in most cancers and genetic illness analysis, and anticipated enhancements to OGM over time; (2) the flexibility and utility of OGM to be complementary to, or utilized in lieu of, conventional cytogenomics strategies for evaluation of structural variations; (3) the utility and talent of the VIA software program to offer genome evaluation with excessive decision and sensitivity, a easy workflow, and improved turnaround instances; (4) the utility and talent of our new compute answer with elevated information processing capabilities, which was co-developed to help larger throughput OGM devices; (5) improved turnaround instances our potential to remain in entrance of opponents’ enhancements in applied sciences; (6) the anticipated advantages and supreme success of our collaborations; (7) our future merchandise and options; and (8) different statements that aren’t historic details.​

Every of those forward-looking statements contain dangers and uncertainties. Precise outcomes or developments could differ materially from these projected or implied in these forward-looking statements. Elements that will trigger such a distinction embrace the dangers and uncertainties related to: (1) the affect of geopolitical and macroeconomic developments, similar to the continued Ukraine-Russia battle, associated sanctions and the COVID-19 pandemic, on our enterprise and the worldwide financial system; (2) challenges inherent in growing, manufacturing and commercializing merchandise; (3) our potential to additional deploy new merchandise and functions and develop the markets for our expertise platforms; (4) third events’ skills to fabricate our devices and consumables; (5) our expectations and beliefs relating to the longer term development of the enterprise and the markets through which we function; (6) the completion and success of our scientific research; (7) the success of merchandise aggressive with our personal; (8) adjustments in our strategic and industrial plans; (9) the applying of usually accepted accounting rules, that are extremely advanced and contain many subjective assumptions; (10) examine outcomes that differ from the examine outcomes referred to on this press launch; and (11) our potential to acquire enough financing to fund our strategic plans and commercialization efforts. We’re beneath no obligation to replace any of those forward-looking statements after the date they’re made to adapt these statements to precise outcomes or revised expectations, besides as required by regulation. It is best to, due to this fact, not depend on these forward-looking statements as representing our views as of any date subsequent to the date the statements are made. Furthermore, besides as required by regulation, neither we nor some other particular person assumes accountability for the accuracy and completeness of the forward-looking statements contained on this press launch.​

CONTACTS

Firm Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Amy Conrad
Juniper Level
+1 (858) 366-3243
amy@juniper-point.com

A photograph accompanying this announcement is accessible at https://www.globenewswire.com/NewsRoom/AttachmentNg/965c4b2e-d363-40d1-9d59-1f9f8a5e0365